CD274 and neoplasm: To further understand the tumor immune microenvironment contributing to the difference in outcome between CRC patients with high and low PD-L1 expression, the oncomine immune response research assay, a targeted NGS assay analyzing the expression of 395 genes associated with the immune response, was applied on the primary CRC tumor samples.